Genetically engineered Pseudomonas: a factory of new bioplastics with broad applications
Article first published online: 7 JUL 2008
Volume 3, Issue 10, pages 612–618, October 2001
How to Cite
Olivera, E. R., Carnicero, D., Jodra, R., Miñambres, B., García, B., Abraham, G. A., Gallardo, A., Román, J. S., García, J. L., Naharro, G. and Luengo, J. M. (2001), Genetically engineered Pseudomonas: a factory of new bioplastics with broad applications. Environmental Microbiology, 3: 612–618. doi: 10.1046/j.1462-2920.2001.00224.x
- Issue published online: 7 JUL 2008
- Article first published online: 7 JUL 2008
- Received 28 June, 2001; accepted 30 July, 2001.
New bioplastics containing aromatic or mixtures of aliphatic and aromatic monomers have been obtained using genetically engineered strains of Pseudomonas putida. The mutation (–) or deletion (Δ) of some of the genes involved in the β-oxidation pathway (fadA−, fadB−ΔfadA or Δfad BA mutants) elicits a strong intracellular accumulation of unusual homo- or co-polymers that dramatically alter the morphology of these bacteria, as more than 90% of the cytoplasm is occupied by these macromolecules. The introduction of a blockade in the β-oxidation pathway, or in other related catabolic routes, has allowed the synthesis of polymers other than those accumulated in the wild type (with regard to both monomer size and relative percentage), the accumulation of certain intermediates that are rapidly catabolized in the wild type and the accumulation in the culture broths of end catabolites that, as in the case of phenylacetic acid, phenylbutyric acid, trans-cinnamic acid or their derivatives, have important medical or pharmaceutical applications (antitumoral, analgesic, radiopotentiators, chemopreventive or antihelmintic). Furthermore, using one of these polyesters (poly 3-hydroxy-6-phenylhexanoate), we obtained polymeric microspheres that could be used as drug vehicles.